Insmed Incorporated
INSM
Rangering i aksjer
#1109
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aksjekurs
$95.88
Markedsverdi
$20.94B
Endring (1 dag)
0.61%
Endring (1 år)
-42.90%
Land
US
Handel Insmed Incorporated (INSM)
Kategori
Healthcare
Historikk for aksjesplitt for Insmed Incorporated (INSM)
Aksjen Insmed Incorporated (symbol: INSM) har gjennomgått totalt 2 aksjesplitt.
Den nyeste splittelsen skjedde Mar 03, 2011.
Én INSM-aksje kjøpt før Jul 31, 2000 tilsvarer i dag 0.025 INSM-aksjer.
Den nyeste splittelsen skjedde Mar 03, 2011.
Én INSM-aksje kjøpt før Jul 31, 2000 tilsvarer i dag 0.025 INSM-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| 2011-03-03 | 1:10 | x0.1 | x0.025 |
| 2000-07-31 | 1:4 | x0.25 | x0.25 |
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
